Brightline-2: A phase IIa/IIb, open-label trial of the MDM2-p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma, or other selected solid tumours Meeting Abstract
| Authors: | Macarulla, T.; Harding, J.; Morizane, C.; Ohkawa, K.; Ueno, M.; Vogel, A.; Lamarca, A.; Yamamoto, N.; Javle, M.; Hu, J.; Teufel, M.; Märten, A.; Goyal, L.; Yoo, C. |
| Abstract Title: | Brightline-2: A phase IIa/IIb, open-label trial of the MDM2-p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma, or other selected solid tumours |
| Meeting Title: | 25th World Congress on Gastrointestinal Cancer (ESMO 2023) |
| Keywords: | oncology |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Jun 28-Jul 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-06-01 |
| Start Page: | S33 |
| Language: | English |
| ACCESSION: | WOS:001037960400057 |
| DOI: | 10.1016/j.annonc.2023.04.112 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P-56 -- Source: Wos |
